Detailed information for compound 211859

Basic information

Technical information
  • TDR Targets ID: 211859
  • Name: 6-[(2-amino-1H-imidazol-3-ium-3-yl)methyl]-5- bromo-1H-pyrimidine-2,4-dione
  • MW: 287.093 | Formula: C8H9BrN5O2+
  • H donors: 4 H acceptors: 2 LogP: -0.55 Rotable bonds: 2
    Rule of 5 violations (Lipinski): 1
  • SMILES: O=c1[nH]c(=O)c(c([nH]1)C[n+]1cc[nH]c1N)Br
  • InChi: 1S/C8H8BrN5O2/c9-5-4(12-8(16)13-6(5)15)3-14-2-1-11-7(14)10/h1-2H,3H2,(H4,10,11,12,13,15,16)/p+1
  • InChiKey: CIBOPDUQCNMGFE-UHFFFAOYSA-O  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 6-[(2-azanyl-1H-imidazol-3-ium-3-yl)methyl]-5-bromo-1H-pyrimidine-2,4-dione
  • 6-[(2-amino-1H-imidazol-3-ium-3-yl)methyl]-5-bromo-uracil
  • 6-[(2-amino-3H-imidazol-1-ium-1-yl)methyl]-5-bromo-1H-pyrimidine-2,4-dione
  • 6-[(2-amino-3H-imidazol-1-ium-1-yl)methyl]-5-bromo-uracil

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Escherichia coli thymidine phosphorylase Starlite/ChEMBL References
Homo sapiens thymidine phosphorylase Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Mycobacterium ulcerans thymidine phosphorylase Get druggable targets OG5_131632 All targets in OG5_131632
Echinococcus granulosus thymidine phosphorylase Get druggable targets OG5_131632 All targets in OG5_131632
Echinococcus multilocularis thymidine phosphorylase Get druggable targets OG5_131632 All targets in OG5_131632
Mycobacterium tuberculosis Probable thymidine phosphorylase DeoA (tdrpase) (pyrimidine phosphorylase) Get druggable targets OG5_131632 All targets in OG5_131632
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Loa Loa (eye worm) aspartic protease BmAsp-2 0.0561 0.2542 1
Leishmania major trypanothione reductase 0.0135 0 0.5
Schistosoma mansoni memapsin-2 (A01 family) 0.0152 0.0098 0.0098
Mycobacterium ulcerans thymidine phosphorylase 0.1531 0.8324 1
Plasmodium falciparum plasmepsin VII 0.0152 0.0098 0.0387
Toxoplasma gondii eukaryotic aspartyl protease superfamily protein 0.0152 0.0098 0.0387
Toxoplasma gondii aspartyl protease ASP1 0.0561 0.2542 1
Trypanosoma brucei trypanothione reductase 0.0135 0 0.5
Plasmodium falciparum plasmepsin X 0.024 0.0623 0.2452
Plasmodium falciparum plasmepsin IV 0.0561 0.2542 1
Plasmodium falciparum plasmepsin V 0.0152 0.0098 0.0387
Toxoplasma gondii aspartyl protease ASP3 0.024 0.0623 0.2452
Plasmodium falciparum plasmepsin VI 0.0561 0.2542 1
Onchocerca volvulus 0.0152 0.0098 0.5
Brugia malayi aspartic protease BmAsp-1, identical 0.0152 0.0098 1
Plasmodium vivax aspartyl proteinase, putative 0.0561 0.2542 1
Plasmodium vivax plasmepsin V, putative 0.0152 0.0098 0.0387
Echinococcus granulosus thymidine phosphorylase 0.1531 0.8324 1
Mycobacterium leprae Probable anthranilate phosphoribosyltransferase TrpD 0.0432 0.1771 0.5
Loa Loa (eye worm) hypothetical protein 0.0152 0.0098 0.0387
Plasmodium vivax plasmepsin IV, putative 0.0561 0.2542 1
Schistosoma mansoni subfamily A1A unassigned peptidase (A01 family) 0.0152 0.0098 0.0098
Trypanosoma cruzi trypanothione reductase, putative 0.0135 0 0.5
Mycobacterium tuberculosis Probable thymidine phosphorylase DeoA (tdrpase) (pyrimidine phosphorylase) 0.1531 0.8324 1
Plasmodium falciparum plasmepsin IX 0.024 0.0623 0.2452
Mycobacterium tuberculosis Probable anthranilate phosphoribosyltransferase TrpD 0.0432 0.1771 0.2127
Schistosoma mansoni cathepsin D (A01 family) 0.1812 1 1
Schistosoma mansoni subfamily A1A unassigned peptidase (A01 family) 0.0152 0.0098 0.0098
Schistosoma mansoni subfamily A1A unassigned peptidase (A01 family) 0.0152 0.0098 0.0098
Schistosoma mansoni subfamily A1A unassigned peptidase (A01 family) 0.0152 0.0098 0.0098
Brugia malayi Pepsin A precursor 0.0152 0.0098 1
Schistosoma mansoni subfamily A1A unassigned peptidase (A01 family) 0.0152 0.0098 0.0098
Plasmodium falciparum plasmepsin VIII, putative 0.0152 0.0098 0.0387
Brugia malayi hypothetical protein 0.0152 0.0098 1
Plasmodium falciparum plasmepsin I 0.0561 0.2542 1
Plasmodium vivax aspartyl proteinase, putative 0.0152 0.0098 0.0387
Schistosoma mansoni subfamily A1A unassigned peptidase (A01 family) 0.0561 0.2542 0.2542
Brugia malayi hypothetical protein 0.0152 0.0098 1
Toxoplasma gondii aspartyl protease 0.0152 0.0098 0.0387
Plasmodium falciparum plasmepsin III 0.0152 0.0098 0.0387
Plasmodium vivax aspartyl protease, putative 0.0152 0.0098 0.0387
Onchocerca volvulus 0.0152 0.0098 0.5
Trichomonas vaginalis Clan AA, family A1, cathepsin D-like aspartic peptidase 0.0561 0.2542 0.5
Loa Loa (eye worm) hypothetical protein 0.0152 0.0098 0.0387
Echinococcus granulosus cathepsin d lysosomal aspartyl protease 0.0561 0.2542 0.3053
Brugia malayi Eukaryotic aspartyl protease family protein 0.0152 0.0098 1
Plasmodium falciparum plasmepsin II 0.0561 0.2542 1
Loa Loa (eye worm) aspartyl protease 6 0.0152 0.0098 0.0387
Schistosoma mansoni subfamily A1A unassigned peptidase (A01 family) 0.0152 0.0098 0.0098
Echinococcus multilocularis thymidine phosphorylase 0.1531 0.8324 1
Echinococcus multilocularis cathepsin d (lysosomal aspartyl protease) 0.0561 0.2542 0.3053
Schistosoma mansoni subfamily A1A unassigned peptidase (A01 family) 0.0152 0.0098 0.0098
Brugia malayi aspartic protease BmAsp-2, identical 0.0152 0.0098 1
Toxoplasma gondii aspartyl proteinase (eimepsin), putative 0.0561 0.2542 1
Plasmodium vivax aspartyl protease, putative 0.024 0.0623 0.2452
Loa Loa (eye worm) aspartic protease BmAsp-1 0.0152 0.0098 0.0387
Plasmodium vivax aspartyl protease, putative 0.024 0.0623 0.2452
Loa Loa (eye worm) hypothetical protein 0.0561 0.2542 1
Schistosoma mansoni subfamily A1A unassigned peptidase (A01 family) 0.0152 0.0098 0.0098

Activities

Activity type Activity value Assay description Source Reference
AUC (ADMET) = 0.292 ug hr-1 ml-1 Area under concentration-time curve for the compound was measured in mice after intravenous administration of 2 mg/kg ChEMBL. 15658853
AUC (ADMET) = 0.968 ug hr-1 ml-1 Area under concentration-time curve for the compound was measured in mice after oral administration of 20 mg/kg ChEMBL. 15658853
AUC (ADMET) = 1.505 ug hr-1 ml-1 Area under concentration-time curve for the compound was measured in mice after intraperitoneal administration of 10 mg/kg ChEMBL. 15658853
C0 (ADMET) 0 ug ml-1 Concentration of the compound at time 0 was measured in mice after intraperitoneal administration of 10 mg/kg; not available ChEMBL. 15658853
C0 (ADMET) 0 ug ml-1 Concentration of the compound at time 0 was measured in mice after oral administration of 20 mg/kg; not available ChEMBL. 15658853
C0 (ADMET) = 3.751 ug ml-1 Concentration of the compound at time 0 was measured in mice after intravenous administration of 2 mg/kg ChEMBL. 15658853
Cl (ADMET) 0 ml min-1 kg-1 Clearance of the compound at time 0 was measured in mice after intraperitoneal administration of 10 mg/kg; not available ChEMBL. 15658853
Cl (ADMET) 0 ml min-1 kg-1 Clearance of the compound at time 0 was measured in mice after oral administration of 20 mg/kg; not available ChEMBL. 15658853
Cl (ADMET) > 72 ml min-1 kg-1 Clearance of the compound at time 0 was measured in mice after intravenous administration of 2 mg/kg ChEMBL. 15658853
Cmax (ADMET) 0 ug ml-1 Maximum plasma concentration of the compound in mice after intravenous administration of 2 mg/kg; not available ChEMBL. 15658853
Cmax (ADMET) = 0.35 ug ml-1 Maximum plasma concentration of the compound in mice after oral administration of 20 mg/kg ChEMBL. 15658853
Cmax (ADMET) = 5.075 ug ml-1 Maximum plasma concentration of the compound in mice after intraperitoneal administration of 10 mg/kg ChEMBL. 15658853
F (ADMET) NA 0 % Bioavailability in mouse (dose 2 mg/kg i.v.) ChEMBL. 15658853
F (ADMET) = 33 % Bioavailability in mouse (dose 20 mg/kg p.o.) ChEMBL. 15658853
F (ADMET) = 103 % Bioavailability in mouse (dose 10 mg/kg i.p.) ChEMBL. 15658853
IC50 (binding) = 19 nM Inhibitory activity of the compound against Escherichia coli thymidine phosphorylase ChEMBL. 14552762
IC50 (binding) = 19 nM Inhibitory activity of the compound against Escherichia coli thymidine phosphorylase ChEMBL. 14552762
IC50 (binding) <= 0.0187 uM Inhibitory concentration against thymidine phosphorylase of Escherichia coli ChEMBL. 15658853
IC50 (binding) <= 0.0187 uM Inhibitory concentration against thymidine phosphorylase of Escherichia coli ChEMBL. 15658853
IC50 (binding) = 0.019 uM Inhibitory concentration against human thymidine phosphorylase ChEMBL. 15658853
IC50 (binding) = 0.019 uM Inhibitory concentration against human thymidine phosphorylase ChEMBL. 15658853
T max (ADMET) 0 hr Maximum time to attain Cmax of the compound in mice after intravenous administration of 2 mg/kg; not available ChEMBL. 15658853
T max (ADMET) = 1 hr Maximum time to attain Cmax of the compound in mice after oral administration of 20 mg/kg ChEMBL. 15658853
T max (ADMET) = 5 min Maximum time to attain Cmax of the compound in mice after intraperitoneal administration of 10 mg/kg ChEMBL. 15658853
T1/2 (ADMET) = 0.2 hr Half-life of the compound was measured in mice after intravenous administration of 2 mg/kg ChEMBL. 15658853
T1/2 (ADMET) = 1 hr Half-life of the compound was measured in mice after intraperitoneal administration of 10 mg/kg ChEMBL. 15658853
T1/2 (ADMET) = 2.2 hr Half-life of the compound was measured in mice after oral administration of 20 mg/kg ChEMBL. 15658853
Vdss (ADMET) 0 l kg-1 Steady state volume of distribution of the compound was measured in mice after oral administration of 20 mg/kg; not available ChEMBL. 15658853
Vdss (ADMET) 0 l kg-1 Steady state volume of distribution of the compound was measured in mice after intraperitoneal administration of 10 mg/kg; not available ChEMBL. 15658853
Vdss (ADMET) = 1.3 l kg-1 Steady state volume of distribution of the compound was measured in mice after intravenous administration of 2 mg/kg ChEMBL. 15658853

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

2 literature references were collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.